Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Clinical Pharmacokinetics
|
April 1, 1989
Clinical pharmacology of 5-fluorouracil
R B Diasio, B E Harris
Pharmacology & Therapeutics
|
January 1, 1990
Metabolism of pyrimidine analogues and their nucleosides
G C Daher, B E Harris, R B Diasio
Cancer
|
August 1, 1991
Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome
B E Harris, J T Carpenter, R B Diasio
Cancer Research
|
January 1, 1990
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
B E Harris, R Song, S J Soong, et al.
Cancer Research
|
December 1, 1989
Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver
B E Harris, R L Song, S J Soong, et al.
Antimicrobial Agents and Chemotherapy
|
January 1, 1986
Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora
B E Harris, B W Manning, T W Federle, et al.
Journal of Biomedical Materials Research
|
March 1, 1985
Pyruvic acid as an etching agent in clinical dentistry
D H Retief, B E Harris, E L Bradley, et al.
Cancer Research
|
June 1, 1983
Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma
B E Harris, T P Pretlow, E L Bradley, et al.
Biochemical Pharmacology
|
December 15, 1988
Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy
B E Harris, R L Song, Y J He, et al.
Cancer Research
|
January 1, 1985
Enzyme activities in prostatic carcinoma related to Gleason grades
T G Pretlow, B E Harris, E L Bradley, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Clinical Pharmacokinetics
|
April 1, 1989
Clinical pharmacology of 5-fluorouracil
R B Diasio, B E Harris
Pharmacology & Therapeutics
|
January 1, 1990
Metabolism of pyrimidine analogues and their nucleosides
G C Daher, B E Harris, R B Diasio
Cancer
|
August 1, 1991
Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome
B E Harris, J T Carpenter, R B Diasio
Cancer Research
|
January 1, 1990
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
B E Harris, R Song, S J Soong, et al.
Cancer Research
|
December 1, 1989
Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver
B E Harris, R L Song, S J Soong, et al.
Antimicrobial Agents and Chemotherapy
|
January 1, 1986
Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora
B E Harris, B W Manning, T W Federle, et al.
Journal of Biomedical Materials Research
|
March 1, 1985
Pyruvic acid as an etching agent in clinical dentistry
D H Retief, B E Harris, E L Bradley, et al.
Cancer Research
|
June 1, 1983
Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma
B E Harris, T P Pretlow, E L Bradley, et al.
Biochemical Pharmacology
|
December 15, 1988
Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy
B E Harris, R L Song, Y J He, et al.
Cancer Research
|
January 1, 1985
Enzyme activities in prostatic carcinoma related to Gleason grades
T G Pretlow, B E Harris, E L Bradley, et al.
Page
of 1